Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average rating of “Buy” from the five research firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.80.
CARM has been the subject of a number of recent research reports. HC Wainwright cut their price objective on shares of Carisma Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. BTIG Research initiated coverage on shares of Carisma Therapeutics in a research note on Thursday, April 11th. They set a “buy” rating and a $6.00 target price on the stock.
Read Our Latest Stock Analysis on Carisma Therapeutics
Institutional Trading of Carisma Therapeutics
Carisma Therapeutics Trading Down 0.6 %
Shares of CARM stock opened at $1.69 on Thursday. Carisma Therapeutics has a 1 year low of $1.65 and a 1 year high of $9.77. The firm has a fifty day moving average price of $2.27 and a 200-day moving average price of $2.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.06 and a quick ratio of 5.06. The company has a market cap of $70.21 million, a price-to-earnings ratio of -0.49 and a beta of 0.95.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.
Recommended Stories
- Five stocks we like better than Carisma Therapeutics
- Transportation Stocks Investing
- United Airlines Soars on Earnings Beat
- When to Sell a Stock for Profit or Loss
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.